ALK is altered in 2.86% of cervical squamous cell carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is altered in 1.75% of cervical squamous cell carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 2.2% of cervical squamous cell carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is altered in 1.76% of cervical squamous cell carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MET is altered in 2.26% of cervical squamous cell carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is altered in 2.23% of cervical squamous cell carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RNF43 is altered in 2.13% of cervical squamous cell carcinoma patients [2].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is altered in 2.86% of cervical squamous cell carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].